Natera, Inc. $NTRA Shares Purchased by Pura Vida Investments LLC

Pura Vida Investments LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 9,727.6% during the second quarter, Holdings Channel reports. The institutional investor owned 245,691 shares of the medical research company’s stock after acquiring an additional 243,191 shares during the period. Natera comprises about 3.8% of Pura Vida Investments LLC’s portfolio, making the stock its 4th biggest position. Pura Vida Investments LLC’s holdings in Natera were worth $422,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Mackenzie Financial Corp grew its holdings in shares of Natera by 9.5% in the 1st quarter. Mackenzie Financial Corp now owns 4,727 shares of the medical research company’s stock worth $668,000 after acquiring an additional 410 shares during the period. Vestcor Inc purchased a new stake in Natera during the first quarter worth $326,000. Natixis Advisors LLC grew its holdings in Natera by 1.8% in the first quarter. Natixis Advisors LLC now owns 30,822 shares of the medical research company’s stock valued at $4,359,000 after purchasing an additional 558 shares during the last quarter. Harbour Investments Inc. grew its holdings in Natera by 57.5% in the first quarter. Harbour Investments Inc. now owns 983 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 359 shares during the last quarter. Finally, US Bancorp DE increased its position in shares of Natera by 2.1% in the first quarter. US Bancorp DE now owns 8,498 shares of the medical research company’s stock valued at $1,202,000 after buying an additional 172 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $240.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 25th. BTIG Research lifted their price objective on Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group upped their target price on Natera from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Fifteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $220.88.

Insider Buying and Selling at Natera

In other Natera news, Director Roy D. Baynes sold 7,668 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the completion of the sale, the director owned 18,359 shares of the company’s stock, valued at approximately $4,095,525.72. The trade was a 29.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the sale, the chief executive officer owned 144,816 shares of the company’s stock, valued at $28,957,407.36. The trade was a 52.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 308,366 shares of company stock worth $63,050,068. 5.63% of the stock is currently owned by company insiders.

Natera Price Performance

NTRA opened at $245.06 on Monday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $241.28. The business has a 50-day moving average of $192.49 and a two-hundred day moving average of $170.91. The stock has a market capitalization of $33.82 billion, a price-to-earnings ratio of -107.01 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. Equities research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.